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Dendritic cells (DCs) were initially defined as mononuclear phagocytes with a dendritic
morphology and an exquisite efficiency for naïve T-cell activation. DC encompass several
subsets initially identified by their expression of specific cell surface molecules and later
shown to excel in distinct functions and to develop under the instruction of different
transcription factors or cytokines. Very few cell surface molecules are expressed in a
specific manner on any immune cell type. Hence, to identify cell types, the sole use of
a small number of cell surface markers in classical flow cytometry can be deceiving.
Moreover, the markers currently used to define mononuclear phagocyte subsets vary
depending on the tissue and animal species studied and even between laboratories.
This has led to confusion in the definition of DC subset identity and in their attribution
of specific functions. There is a strong need to identify a rigorous and consensus way
to define mononuclear phagocyte subsets, with precise guidelines potentially applicable
throughout tissues and species. We will discuss the advantages, drawbacks, and com-
plementarities of different methodologies: cell surface phenotyping, ontogeny, functional
characterization, and molecular profiling. We will advocate that gene expression profiling
is a very rigorous, largely unbiased and accessible method to define the identity of
mononuclear phagocyte subsets, which strengthens and refines surface phenotyping. It
is uniquely powerful to yield new, experimentally testable, hypotheses on the ontogeny or
functions of mononuclear phagocyte subsets, their molecular regulation, and their evolu-
tionary conservation. We propose defining cell populations based on a combination of cell
surface phenotyping, expression analysis of hallmark genes, and robust functional assays,
in order to reach a consensus and integrate faster the huge but scattered knowledge
accumulated by different laboratories on different cell types, organs, and species.
Keywords: mononuclear phagocytes, comparative genomics, human, non-human primates, mouse, pig, sheep,
chicken
Introduction
The immune system includes a large variety of myeloid and lymphoid cell types which develop
through distinct ontogenic pathways, express specific phenotypes, and exert specialized functions.
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The mononuclear phagocytes form a complex group of myeloid
cells that encompass three major cell types, i.e., monocytes,
macrophages, and dendritic cells (DC), together with their proxi-
mal progenitors. These three cell types contribute tomaintain host
integrity by shaping the innate and adaptive immune defense, a
generic function related to their common phagocytic properties
and their capacity to present antigen to T cells. These functions are
also shared by other types of professional antigen-presenting cells
(APCs), in particular B lymphocytes. However, different types
of APCs are primarily devoted to distinct functions (Figure 1).
B cells produce antibodies. Monocytes patrol the organism for
the detection of pathogens and dominantly display inflamma-
tory and oxidative stress response. Macrophages mainly perform
microbicidal, scavenging, and tissue trophic/maintenance func-
tions. DC are uniquely efficient for antigen-specific activation
of naïve T lymphocytes, a process called T-cell priming. Indeed,
DC were initially defined by their dendritic morphology and
their exquisite capacity for T-cell priming. DC include two main
cell types, the plasmacytoid DC (pDC) that are expert in type I
interferon synthesis upon viral stimulation and the conventional
DC (cDC) that are specialized in antigen capture, processing, and
presentation for T-cell priming. Two cDC subsets can be distin-
guished based on a further segregation of functions. XCR1+ cDC1
are particularly efficient in CD8+ T-cell activation and cross-
presentation, at least in mice. XCR1  cDC2 are most efficient for
T helper cell priming, in particular polarization toward Th2 or
Th17, and for the promotion of humoral immunity. Importantly,
an additional layer of complexity is generated by the plasticity
of the different mononuclear cell types, which display modified
phenotypes and functions contingent to the anatomical microen-
vironment where they reside or when exposed to pathogens or
inflammation. For instance, monocytes adopt a dendritic mor-
phology and antigen-presentation functions in inflammatory set-
tings (1–3) as well as when located in the dermis (4–6), leading
to their designation as monocyte-derived DC (MoDC). Langer-
hans cells, long considered to be DC due to their morphology
and antigen-presentation function, are now known as a type of
tissue macrophages (7–13). More generally, the gene expression
programs, phenotypes, and functional properties of macrophages
are strongly influenced by their tissue of residence. Finally, not
only XCR1+ cDC but also other DC subsets including pDC and
XCR1  cDC can also efficiently cross-present antigens to CD8+
T cells when appropriately stimulated (14–22). Thus, the plasticity
of the mononuclear phagocyte responses superimposes onto the
segregation of phenotypes and functions attributed to subsets
(Figure 2), which can lead to confusion in the definition of the
different cell types if only based on functional assays. Hence, mor-
phologic, phenotypic, and functional criteria are not sufficient to
rigorously definemononuclear phagocyte subsets, and to properly
discriminate what are distinct cell types as opposed to different
developmental or activation states of a given cell type. Comple-
mentary or robust alternative criteria are needed to rigorously
define the identity of the mononuclear phagocyte subsets.
Mononuclear phagocyte subsets were recently shown to
develop from distinct progenitors and/or under the instruction
of different transcription factors or cytokines. cDC and pDC
derive from a dedicated bone marrow precursor, the commonDC
progenitor, with a differentiation potential strictly restricted to
this hematopoietic lineage. pDC and cDC homeostasis exquisitely
depends on the growth factor FLT3-L. pDC development strictly
depends on the transcription factors TCF4 (E2-2) and SPIB both
in mouse and human, XCR1+ cDC development on the mas-
ter transcription factor IRF8 at least in mice, and XCR1  cDC
development on IRF4. Macrophages derive from a monocytic
precursor, either of embryonic origin as in the case of Langerhans
cells and microglia, or at least in part from circulating blood
monocytes as in the case of gut macrophages. Egress of clas-
sical monocytes from the bone marrow into the blood strictly
depends on the chemokine receptor CCR2. As a consequence, in
competitive mixed bone marrow reconstitution experiments in
mice, all cell types derived from circulating blood monocytes are
primarily reconstituted from wild-type cells and not from CCR2-
deficient cells. Hence, it has been proposed that the study of their
developmental pathway, in other words ontogeny, was the best
way to classify mononuclear phagocyte cell types, at least in the
mousemodel where the knowledge inDC subset properties is also
the most advanced. Indeed, in this model, genetically modified
animals unambiguously permit to track the development of cell
types and to dissect their phenotypes and functions, in different
contexts in vivo. However, the identity and functions of the differ-
entmononuclear phagocyte subsets need to be established outside
of the mouse model, in animal species where ontogenic studies
cannot be easily conducted, in order to accelerate translation of
our advanced knowledge on the functioning of themouse immune
FIGURE 1 | Different types of APCs are specialized in distinct primary functions. cDC are uniquely efficient for the priming and functional polarization of T
cells. Although other APCs also contribute to this process, this does not represent their primary functions. Hence, cDC play a central and non-redundant role in the
orchestration of adaptive immunity.
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FIGURE 2 | Combined functional specialization and plasticity of DC
subsets allows mounting different types of adaptive immune responses
adapted to the various natures of the threats to be faced. (A) Five DC
subsets can be defined in mice based in part on their functional specialization:
pDC, XCR1+ cDC, XCR1  cDC, MoDC, and Langerhans cells. Certain DC
subsets are more efficient than others to exert a specific function, because they
are intrinsically genetically built to activate this function faster and in more
diverse settings. (B) The function of each DC subset is relatively plastic. Three
types of output signals are delivered by DC to T cells and instruct their functional
polarization: (1) ligands for the T-cell receptor (antigenic peptides presented in
association with MHC molecules), (2) co-stimulation, and (3) cytokines.
Co-stimulation and cytokine signals can be either activating (e.g., CD86 and
IL-12, respectively) or inhibitory (e.g., PD-L1 and IL-10, respectively). Different
cytokines induce distinct types of helper T-cell responses. For example, IL-12
primarily promotes Th1, IL-4 promotes Th2, and IL-23 promotes Th17. Each DC
subset can sense a specific array of microbial or danger signals. Integration of
the particular combination of input signals received by the DC in a given
pathophysiological context determines the precise type of maturation ensuing
and hence the combination of output signals delivered to T cells. As a result,
different DC subsets can exert similar or complementary functions depending
on the physiopathological context. (C) The combination of functional
specialization and plasticity of subsets allows DC responses to be highly flexible
and thus to react rapidly to different threats by coupling the type of danger
sensed to the most appropriate type of immune response to induce for
protection. However, this flexibility can lead to confusion if attempting to define
DC subsets only on functional specialization. NOI, nitric oxide intermediates;
ROI, radical oxygen intermediates; Th, T helper cell; Tc, cytotoxic T cell; Treg,
regulatory T cell; Ts, T suppressor cell.
system toward clinical and/or economical applications to sustain
global human health. Very promising vaccine and immunomod-
ulatory strategies have been developed in mouse models based on
DC subset targeting (23–35). The translation of these strategies to
human and other species has not yet reached the expected success,
likely due to insufficient knowledge in the identity and function of
homologous DC subsets across species. This knowledge is needed
in biomedical model species, primarily in non-human primates,
and also in alternative models such as pigs that share physiolog-
ical and anatomical similarities with humans – for instance skin
and lung structural properties – and that present sensitivity to
human pathogens of great importance for public health such as
influenza. In addition, this knowledge is needed for companion
and sport animals, and for animals of the agro-economy, such
as ruminants, pigs, poultry, and fishes, with the goal to improve
vaccination strategies against pathogens responsible for major
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economic losses, to decrease antibiotic use and to ameliorate ani-
mal welfare. These species, as well as wild animals, are also targets
or reservoirs for major zoonotic pathogens whose control could
thus benefit from new vaccine strategies targeting DC subsets in
these animal species. This raises the question how to best define
DC subset identity and functions in a way that can be extrapolated
from mouse to human and other species, for clinical applications
as well as for a better understanding of the evolution of the
immune system.
Different Methodologies to Define the
Identity of Immune Cell Types, with Their
Advantages and Drawbacks
Several methodologies have been proposed to define cell types.
They include cell surface phenotyping andmorphology, ontogeny,
functional characterization, molecular profiling at population
level, and molecular profiling at single cell level. We will discuss
the specific drawbacks and advantages of each of these approaches
(Table 1).
Cell Surface Phenotyping and Morphology
Cell surface phenotyping generally is a mandatory first step for
all other proposed methodologies aiming at defining DC subsets.
It may be skipped only for particular experiments of molecular
profiling at single cell level and perhaps for functional tests based
on validated protocols for specific depletion of the targeted cell
subset in vivo. Indeed, phenotypic characterization/identification
of DC subsets is necessary either to purify them formorphological
analysis, functional assays, or molecular profiling, or to compare
their characteristics in tissues or bulk cell suspensions (expression
of lineage reporters in cell fate mapping experiments, anatomi-
cal location, maturation status, cytokine production, interactions
with T cells: : :). Phenotypic characterization through cell surface
phenotyping by flow cytometry is the method of DC subset iden-
tification the easiest to perform and the most frequently used.
No single cell surface marker has been found to be sufficient for
identification of a givenDC subset, except for XCR1 expression on
mouse andhumanXCR1+ cDC (18, 36–42) andmaybeBDCA2or
LILRA4 expression on human pDC (43–46). Thus, to rigorously
identify any given DC subset in any species with a limited risk
of contamination by another cell type, most of the time complex
combinations of multiple markers are required, often including
the use of exclusion marker to ensure lack of contamination
of the cell population targeted by other cell types sharing with
it many positive markers. For example, the CD8α+ subset of
mouse pDC can heavily contaminate mouse lymphoid organ-
resident XCR1+ cDC when defined phenotypically as Lineage 
CD11c+CD8α+ (47–49). This problem can be solved by exclu-
sion of SiglecH+ or CCR9+ cells or by using XCR1 as a positive
marker. Similarly, other cells including MoDC or activated CD1c
(BDCA1)+ XCR1  cDC can heavily contaminate human XCR1+
cDC when defined phenotypically as Lineage  HLA-DR+CD141
(BDCA3)+ (41, 50, 51). This problem can be solved by using
CADM1 or XCR1 as additional positive markers (41, 52). Rigor-
ous phenotypic identification of XCR1  cDC (mouse CD11b+
cDC and human CD1c+ cDC) can be much more challenging,
since these cells can be difficult to discriminate from MoDC,
in particular under inflammation settings (53, 54). Identification
of DC based on oligoparameter phenotyping is even more at
risk of inaccuracy in other species, due to the limited panel of
available antibodies directed to surface markers and to the poor
knowledge in surfacemarker expression selectivity in non-DC cell
types. However, major advances have recently beenmade to refine
strategies forDC subset identification by cell surface phenotyping,
in part based on novel knowledge gained through ontogeny and
molecular profiling studies as will be discussed below. Hence,
protocols for DC subset identification by cell surface phenotyping
might soon become standardized, at least in mouse and human.
This would allow better comparison of data across laboratories
and limit the risk of use of inappropriate protocols leading to
improper data interpretation. Special attention should be given
to enzymatic dissociation that can strongly modify cell surface
marker detection. Ideally, universal phenotyping protocols could
be designed, allowing to considerably simplify the current nomen-
clatures for DC subsets by using the same name and similar
marker combinations to identify homologous cell types irrespec-
tive of their tissues and species of origin (55–57). Moreover, the
markers used to define and name DC subsets could be chosen
based on their relevance to the biology of these cells, contrary
to the current situation where the markers used were discovered
fortuitously/empirically and may not be linked to the biology of
the eponymous cells, as is the case for CD8α and CD141 for
mouse and human XCR1+ cDC, respectively. However, when
identifying a potentially new subset of DC or studying in a novel
context a potentially known DC subset, a number of precautions
need to be taken for data interpretation, including confirmation
of conclusions by complementary methods such as ontogeny,
functional, or molecular profiling studies.
Ontogeny
Ontogeny studies in mice, in particular studies on the depen-
dence of DC subset development on transcription factors, have
been instrumental in identifying the homologies between lym-
phoid tissue-resident CD8α+ cDC and the CD103+CD11b 
cDC present in non-lymphoid tissues and migrating into the
draining lymph nodes once activated (58). These studies, together
with gene expression profiling analyses (9, 40), ultimately
allowed grouping mouse CD8α+ cDC and CD103+CD11b 
cDC together under the umbrella of the XCR1+ cDC subset (38,
40, 59, 60). The recent discrimination of mouse CD11b+ cDC
from MoDC has also been largely based on the analysis of the
role of specific chemokine or growth factor receptors on cell type
development in vivo, namely CCR2 dependence as a characteristic
of monocytic origin and FLT3 dependence as a proof of cDC
identity (2, 3, 6, 61). In addition, mouse CD11b+ cDC develop-
ment was shown to selectively depend on the IRF4 transcription
factor (62, 63). Moreover, the establishment of the concept that
mouse bona fide DC constitute a separate hematopoietic lineage,
and the discrimination betweenmouse CD11b+ cDC andMoDC,
were confirmed using mutant animals allowing to track natural
precursor–progeny relationships in vivo through irreversible flu-
orescent tagging of all daughter cells of a given type of hematopoi-
etic progenitor, based on Cre-mediated conditional activation
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TABLE 1 | Different methodologies to define DC subsets with their advantages and drawbacksa.
Methodology
Cell surface
phenotyping
Ontogeny Functional
characterization
Molecular profiling
At the population level At the single cell level
Dependency on
cell surface
phenotyping
Not applicable Yes but methodology
allows assessing the
risk of cell type
cross-contamination
Yes, risk of bias Yes, risk of bias No
Data quality heavily
depends on rigor of the
cell surface phenotyping
procedure used to identify
cell types
Data quality heavily
depends on rigor of the
cell surface phenotyping
procedure used to identify
cell types. A posteriori
analyses can allow
rigorously assessing
the risk of cell type
cross-contamination
Ab initio identification of
cell types without use of
prior knowledge on their
identity
Experimental
feasibility
Good Difficult for most
species except mouse
Depends on the species
studied and the functions
tested
Good
Needs comparison with
sister cell types and
potential contaminants
Challenging both for data
generation and data analysis.
Commercial solutions exist
for data generation but are
expensive
Needs to balance cost and
sequencing depth. Data
analysis still in a large part
dependent upon knowledge
from molecular profiling at the
population level
Protocol
standardization
Achievable soon but
currently limited.
Currently used markers
defined
fortuitously/empirically,
generally unrelated to
cell biology, and different
between tissues,
species, and laboratories
Difficult Difficult Good Should happen upon
technology maturation and
democratization
The most subject to
variations. Multiplicity of
protocols depending on
the functions tested, the
tissues used and the
species studied including
its genetics, and even on
the laboratories
Routine technology for
data generation
Democratization of
bioinformatics analyses
Frequency of
use
Most frequent Mostly by specialists Frequent Increasing frequency Very rare but high potential
Depending on the species
studied and the functions
tested
Advancement of
knowledge
The less informative Generally
dichotomic
information allowing
relatively easy
classification.
Relevant to cell
biology
Yes Yes Yes
The most relevant for
clinical and veterinary
applications
Generation of novel
hypotheses on the
ontogeny or functions
of cells and their
molecular regulation.
Identification of
conserved and
biologically relevant cell
surface markers.
Identification of
candidate molecular
targets to manipulate
cell functions
Same advantages as
molecular profiling at the
population level.
In addition,
i) unbiased identification of
cell types and associated
transcriptomic signatures,
ii) strong potential for
identification of new cell
types, iii) evaluation of
intra-cell type
heterogeneity, and
iv) rigorous identification
of cellular modules
constituted of genes
co-expressed in single
cells and contributing to
the same biological
function
aAdvantages are indicated in bold font and drawbacks in plain font.
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of a floxed reporter gene under the control of the constitutive
Rosa26 promoter, an experimental strategy-coined fate mapping
(64). Based on the important contribution of ontogenic studies for
rigorous delineation of the identity of mouse DC subsets and of
their lineage relationships, it has been proposed to use ontogeny
as a primary methodology for the classification of mononuclear
cell subsets in all species (57). Recent methodological progress
has now made rigorous ontogenic studies applicable to human
DC subsets, by using surrogate models of DC development from
human CD34+ hematopoietic progenitors, either in vitro (41, 65,
66) or in vivo in alymphoid mice (66–68). Such approaches have
allowed demonstrating remarkable similarities in the ontogeny of
mouse and human DC subsets. For example, knock-down exper-
iments performed by transducing human CD34+ hematopoietic
progenitors with shRNA-expressing lentiviral vectors allowed to
show that human pDC development critically depends on the
transcription factor SPIB including in vivo in humanized mice
(67), and that human XCR1+ cDC development depends on the
transcription factor BATF3 in vitro but not in vivo in humanized
mice (68). Moreover, the pathway for the development of human
pDC, XCR1+ cDC, and XCR1  cDC was very recently demon-
strated to be similar to that described for mouse DC subsets, with
the identification of the human homologs to the mouse common
DC progenitor and pre-cDC (66, 69). The role of candidate genes
susceptible to affect DC development can even be assessed in vivo
in humans in the rare cases where patients have been identi-
fied with primary immune deficiencies resulting from natural
mutations in such genes (70). Strategies are being developed to
actively search for human primary immunodeficiencies affecting
DC development as experiments of nature allowing decipher-
ing the molecular mechanisms regulating this biological process
(71). However, ontogenic studies will often not be applicable in
human for rigorous assessment of the identity of DC subsets,
for example when studying a potentially known DC subset in
a novel physiopathological context, including characterization of
the DC subsets present in steady-state non-lymphoid tissues (50)
or infiltrating tumors and their draining lymph nodes (72, 73)
or isolated from infected/inflamed tissues. In addition, rigorous
ontogenic studies will be very difficult to perform inmany species,
because (i) precursor/progeny relationships remain very difficult
to evaluate in vivo through cell fatemapping or cell transfer experi-
ments, (ii) in vivo analysis of cell subset development dependence
on growth factors or transcription factors cannot be reasonably
done due to operational and/or financial reasons, and (iii) in vitro
models of bona fide DC development are currently lacking (74).
Hence, the use of other methodologies will be necessary to prove
DC subset identity in these various conditions.
Functional Characterization
Ideally, cell types should be defined based on the array of functions
they can exert, because this definition links identity to function
and is hence the most relevant to understand the functioning of
the immune system and to harness the biology of DC subsets for
improving health care of humans and of other species. In addition,
cell type definitions based on their functional specialization could
be the most universal across tissues and species. However, func-
tional assays are often the hardest to perform experimentally and
can be the most subject to variations depending on assays and
experimental conditions. This is especially the case for assays
aiming at comparing the ability of different DC subsets to activate
T cells. If one aims at precisely comparing the cell-intrinsic ability
of different DC subsets to process and present antigens, a number
of potentially confounding factors must be taken into account to
design the experiment in order to reduce the risk of inappropriate
interpretation of results. Adequate steps must be taken to preserve
the viability of DC subsets and control for it. This implies adding
to each isolated DC subset the appropriate cytokines or growth
factors necessary for their survival, for example GM-CSF for cDC
and IL-3 for human pDC. For instance, sorted XCR1+ cDC show
a lower ex vivo survival as compared to XCR1  cDC in mice and
sheep (75, 76). Sorting of DC subset by positive selections may
affect DC subset responses due to antibody-mediated receptor
stimulation (43, 77–79). This also implies including a positive
control consisting in DC subsets pulsed with optimal epitopic
peptides, to assess on antigen-specific T-cell priming by DC the
impact of other factors than DC subset-intrinsic differences in
antigen processing and presentation, not only differences in DC
subset viability but also in delivery of co-stimulation or cytokine
signals. In this regard, for a fair comparison between DC subsets,
they should each be matured by stimulation with an appropri-
ate adjuvant. PolyI:C is much more efficient than LPS for the
activation of human XCR1+ DC while it is the reverse for the
activation of human MoDC. TLR7 or TLR9 ligands, but not
TLR3 or TLR8 ligands, are potent activators of human pDC.
Another layer of complexity is due to fundamental differences
in the design of experiments in different species. While the gold
standard for antigen processing and presentation assays in mice
is the measurement of the activation of TcR-transgenic naïve
T cells, this is not possible in other species where various sur-
rogate readouts are used including antigen-specific re-activation
of antigen-experienced T-cell clones or polyclonal T-cell lines or
even proliferation of allogeneic T cells. It is known that significant
differences exist in mice in the signals required for naïve T-cell
priming, antigen-experienced T-cell re-activation, or allogeneic
T-cell proliferation induction. Therefore, the same exact function
is not fairly tested in different species. Furthermore, in species
outside mice and humans, the use of epitopic peptide control
requires to have accurate MHC typing and knowledge of the cor-
responding optimal peptides, which are generally unavailable. In
addition, for accessibility reasons, the DC subsets used generally
derived from different anatomic compartments depending on the
species. For example, spleen DC subsets are often used in mice,
blood, or tonsil DC in humans and lymph DC in sheep, which
can further confound rigorous interpretation of the results when
differences are observed between species. Finally, while inbred
mice with defined sanitary status are generally used to limit the
variability of the responses between individuals, this is not the case
for other species including humanswhere the considerable hetero-
geneity in the genotypes, environments, and immune histories of
individuals contribute to the strong variability of their responses
(80). Hence, even for mouse experiments, there is a strong need
for standardization of functional assays assessing the ability of
DC subsets to process and present antigens and to functionally
polarize T cells. Moreover, when attempting to compare DC
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subset functional specialization across two species, efforts should
be made to use comparable experimental designs in both species.
Thus, while functional characterization is highly desirable when
identifying a potentially new subset of DC or studying in a novel
context a potentially known DC subset, the identity of DC subsets
must first be studied through alternative approaches measuring
cell type-specific parameters that are less strongly influenced by
the tissue microenvironment and the genetic or immune history
of populations, and forwhich experimental protocols are relatively
well standardized.
Molecular Profiling at the Population Level
As the ontogeny and functions of cell types are instructed by
specific gene expressionmodules, cell type identity can be defined
by itsmolecular fingerprinting, including through gene expression
profiling (81, 82). Homologous cell types between species can
be defined as “those cells that evolved from the same precursor
cell type in the last common ancestor” (82). This implies that
homologous cell types must exhibit closer molecular fingerprints
and gene expression programs than non-homologous cell types.
Thus, it should be possible to decipher the identity of immune
cell types of virtually all vertebrate species, by establishing their
gene signatures and comparing them to the transcriptomic finger-
prints of the well-characterized immune cell types of the mouse
referent species. This is indeed an approach we pioneered to
compare mouse spleen and human blood DC subsets (39) and
later extended to comparison with sheep lymph cDC subsets
(76), mouse DC subsets across tissues (40), as well as chicken
spleen and pig skin mononuclear phagocyte subsets (83, 84).
This approach allowed us to rigorously demonstrate for the first
time to the best of our knowledge that human CD1c+ cDC and
CD141+ cDC were homologous to mouse CD11b+ cDC and
CD8α+ cDC, respectively (39, 85). This was later confirmed by
us and others based on phenotypic, functional, and ontogeny
studies (18, 37, 50, 65, 86). In addition, this approach permit-
ted to show that cDC split into XCR1+ and XCR1  subsets in
migrating skin lymph DC in sheep, a species belonging to the
Laurasiatherians, which is a mammalian order distant from the
mouse and human Euarchontoglires (76). This approach also
provided the first compelling evidence for existence of bona fide
cDC and macrophages in chicken, showing that diversification in
mononuclear phagocyte cell types appeared in a common ances-
tor to mammals and reptiles (83). Comparative transcriptomics
also led to recognize CADM1 and SIRPα as surface molecules
whose conserved expression throughout distant species can be
used as a first phenotyping step to identify XCR1+ and XCR1 
cDC subsets in any mammal (76). Notably, CADM1 is a highly
conserved molecule, presenting about 90% identity across mam-
malian orthologs, thus allowing using commercial anti-human
CADM1 antibodies for cellular staining in distant species (76, 84).
We found the Xcr1 gene among genes specifically expressed in
mouse spleen CD8α+ DC when compared to a number of other
immune cell types [see Supplementary Material “Additional file
5; gb-2008-9-1-r17-s5.xls” from Robbins et al. (39), specifically in
the “CD8a_DC_gene_signature” established from our microarray
data and confirmed from our own re-analysis of the microarray
dataset independently generated by Dudziak et al. (87)]. Specific
expression of the Xcr1 protein onmouse lymphoid tissue-resident
CD8α+ DC and its functions were first unveiled in the pioneering
report from the group of Kroczek (36), who showed that CD8+
T-cell cross-priming depends on their ability to secrete the Xcr1
ligandXcl1 in experimentalmodels where either theOVA coupled
to an anti-CD205 Ab or OVA-expressing allogeneic pre-B cells
are administrated in vivo. Xcr1 expression on CD8α+ DCs was
also found to be critical for the optimal induction of CD8+ T-
cell responses upon Listeria monocytogenes infection (18). Impor-
tantly, comparative transcriptomics revealed XCR1 as a specific
and universal marker for XCR1+ cDC across tissues and species.
This was initially shown in human, mice, and sheep (18, 37, 76)
and subsequently in non-human primates and pigs (18, 37, 38, 40,
52, 59, 60). Altogether, these studies were critical for the current
proposal of cDC subset classification into XCR1+ and XCR1 
cDC (38, 40). Many other recent studies have demonstrated the
power of gene expression profiling to determine with a high
degree of certainty the identity of mononuclear phagocyte subsets
in a tissue where they had not been rigorously studied before
or to identify homologous subsets of mononuclear phagocytes
across species (5, 6, 8, 9, 50, 88–90). Importantly, standardized
protocols for generation and analysis of gene expression data are
routinely performed in many laboratories, platforms, or commer-
cial companies in many countries. The corresponding costs have
strongly decreased over the last decade and continue to go down.
Hence, gene expression profiling at the population level is a very
robust and reproducible methodology that is feasible in virtually
all species where tools are available or can be developed to phe-
notypically identify and purify candidate cell subsets. However,
potentially confounding factors must be taken into account to
design experiments in order to reduce the risk of inappropriate
interpretation of results (Figure 3). First and foremost, great care
and rigor must be exerted in designing the experimental sam-
pling protocol for cell subset purification, inasmuch as minor
contamination by another cell type can dramatically impact the
gene expression profile obtained. Hence, it is critical to carefully
design the marker combination used to purify the different cell
populations to be studied, and to control cell purity prior to the
generation of the gene expression data. Second, to allow proper
analysis of the gene expression profiles of the targeted cell type,
appropriate cell type controls must be included, encompassing
sister cell types as well as cell types that could be potential con-
taminants due to their expression of several of the markers used
for positive selection of the targeted cell type. These controls are
critical to allow assessing the risk of contamination by another cell
type (49).
Molecular Profiling at the Single Cell Level
Recent technological advances now allow performing high
throughput RNA sequencing at single cell levels with high sen-
sitivity and processivity. Transcriptomic analyses at the single
cell level could solve most of the issues raised in the previous
section for molecular profiling at the population level. Indeed,
because it alleviates the necessity to purify cells on imperfect
and potentially confounding phenotypic marker combinations,
analysis at the single cell level should allow unbiased identification
of potentially all cell types and their associated transcriptomic
signatures. It also solves the issue of cross-contamination between
cell types, since the identity of each single cell is established a
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FIGURE 3 |Workflow for cell type identification by molecular profiling
at the population level. Molecular profiling at the population level can be
very informative for cell type identification. However, inappropriate
interpretation can occur if confounding factors are not taken into account.
Hence, it is critical to carefully design experiments and to establish a rigorous
workflow, including a number of key control samples and quality check
procedures. The experimental sampling protocol must be optimized to
decrease a priori the risk of cross-contamination between cell types or of error
resulting in selection of another cell type than the one wanted. Purity of cell
types must be assessed immediately after sampling (e.g., by flow cytometry).
Positive and negative cell type controls must be included, such as sister cell
types and potential contaminant populations. Once molecular expression data
have been obtained, after technical quality has been validated by classical
controls, additional specific quality controls must be performed to a posteriori
ensure of lack of cross-contamination between cell subsets or to evaluate the
risk of misinterpretation of the results. HCL, hierarchical clustering; PCA,
principal component analysis; GSEA, Gene Set Enrichment Analysis.
posteriori based on the analysis of its gene expression program.
In addition, the generation of gene expression data for many
individual cells of the same type should increase statistical power
to define genes co-expressed at the single cell level and to define
cell type-specific transcriptomic modules (81). As a proof-of-
principle, single cell gene expression profiling recently allowed the
unbiased and de novo identification of the different cell types of
spleen (91) and central nervous system (92, 93) via the description
of theirmolecular identity, starting from the bulk population of all
the cells that could be extracted from the organ without any prior
enrichment procedure. However, molecular profiling at the single
cell level cannot be used without prior phenotype-based enrich-
ment for very rare cell types, and it is difficult to apply to species in
which genome has not yet been completely assembled. To obtain
complete information, including on functionally important genes
for which few mRNA are expressed per cell, it is necessary to
sequence at a sufficient depth of about one million reads per cell,
which today still represents a very high cost when multiplied
by the number of individual cells and conditions. This is all the
more the case since, likewise for molecular profiling at population
level, correct interpretation of the data requires that sister cell
types as well as cell types that could be potential contaminants
are included in the experimental design.Moreover, the technology
for single cell RNA sequencing is not yet democratized, since it is
challenging both for sample preparation and for data analysis. For
standardization of high quality sample preparation, commercial
solutions exist but are very expensive. For data analysis, there is no
consensus yet on how the data should bemathematically modeled
for adequate removal of background signal and for discrimination
of false negative signal due to sampling bias in the pool of the cell
mRNA as opposed to true lack of gene expression. In addition, the
interpretation of the RNA-seq data on single cells is still largely
based on the transcriptomic/molecular identity of cell types that
are deduced from microarray analysis of purified cell pools (91).
Hence, molecular profiling at the population level currently rep-
resents a more sustainable strategy for most laboratories.
Recent Advances Brought by Comparative
Transcriptomics at the Population Level for
Defining the Identity and Functions of
Mononuclear Phagocyte Subsets and
Their Molecular Regulation
In this section, we will reviewmajor advances brought forward by
comparative transcriptomics at the population level for defining
the identity and functions of mononuclear phagocyte subsets and
their molecular regulation.
Gene expression profiling of cell types with apparent ambigu-
ous phenotype or functions allowed to rigorously establish their
identity, which could be achieved properly strictly contingent to
their comparison with all candidate sister cell subsets as well as
more distantly related cell types. Hence, we and others showed
that human blood Lineage-CD16+ cells are non-classical mono-
cytes (39, 88) and not DC as was sometimes claimed (94–96).
Similarly, analysis of human skin CD14+ cell expression of the
transcriptomic fingerprints independently established for cDC,
monocytes, andmacrophages provided critical evidence that these
cells are monocyte-derived macrophages (5) while they were pre-
viously designated as DC (4). Transcriptomic analyses were also
instrumental to demonstrate the homology of this human dermal
cell type with the murine CD11b+Ly6C CD64lo–hi (6) and pig
CD163+ (84) skin subsets. We were also able to show that cell
populations claimed to correspond to novel cell types actually
corresponded to a distinct differentiation or activation state of
an already known cell type, for example establishing that the
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so-called interferon killer DC correspond to a particular activa-
tion state of NK cells (39). Furthermore, we showed that, upon
many types of in vivo or in vitro stimulation, human and murine
pDC and cDC undergo a remodeling of their gene expression
program related to their plasticity, including induction of NFκB
and IFN target genes, but still keep the canonical gene expression
associated to their subset identity (41, 97). In particular, contrary
to what other researchers hypothesized (98), gene expression pro-
filing showed that activated pDC are not undergoing a cell fate
conversion into a novel type of cDC (97).
Gene expression profiling also allowed aligning subsets of
mononuclear cells across tissues (6, 8, 9, 40, 55, 99), establishing
cell type homologies across species (5, 39, 50, 76, 83–85, 88, 89,
100), and rigorously examining the proximity of in vitro-derived
subsets of mononuclear cells with those naturally existing in vivo
(39, 41, 66, 101). These studies allowed significantly advancing the
ontogeny and functional characterization of mononuclear phago-
cyte subsets based on the novel hypotheses that can be inferred
from the analysis of the gene expression programs of the cells and
from their comparison with other well-characterized cell types.
The study of the functional specialization of humanDC subsets
was strongly boosted by the demonstration of their transcriptomic
homologies with mouse DC subsets (39, 85) which was recog-
nized as a major breakthrough in the field (37, 53, 102–104) and
acknowledged to have been impossible to draw from studies based
on a limited set of molecular markers (105). In particular, this led
to test whether human XCR1+ cDC could be more efficient for
cross-presentation than other human DC subsets. Even though
the extent to which human XCR1+ cDC are more efficient for
cross-presentation than other human DC subsets is debated, the
results from the functional studies performed independently by
many teams concurrently demonstrate that these cells excel at
cross-presentation of cell-associated antigens (18, 19, 37, 41, 86,
106) and of particulate antigens delivered through FcγR, through
late endosomal targeting (21, 107) or upon polyI:C stimulation
(18, 41, 86, 108). In addition, in sheep, the skin lymph migrat-
ing XCR1+ cDC spontaneously displayed a higher efficiency of
soluble antigen-presentation to specific CD8+ T cells, as com-
pared to XCR1  cDC (76).
Based on the demonstration of the striking transcriptomic
similarities between mouse and human subsets of mononuclear
cells, and onknowledge on the ontogeny of these cells in themouse
(109, 110), we proposed that, similar to their mouse counterparts,
human pDC and cDC constitute a specific family of cells within
the hematopoietic tree, should derive from a common progeni-
tor with a DC-restricted differentiation potential, and could be
derived in vitro fromhumanCD34+ progenitor cells in part under
the instruction of the FLT3-L growth factor (39, 85), all of which
was later confirmed experimentally (41, 65, 66, 69, 111, 112).
Very importantly, comparative genomics of immune cell sub-
sets yielded conserved transcriptomic fingerprints for each of
these cell types (39), a novel knowledge which considerably accel-
erated the deciphering of the molecular mechanisms regulat-
ing the development and functions of leukocytes as reviewed in
Table 2 (18, 36, 59, 100, 113–127). Finally, this approach uniquely
allowed identifying conserved and biologically relevant cell sur-
face markers for each subset of mononuclear cells which could
enable considerably simplifying the nomenclature for DC subsets
by using the same name and similar marker combinations to
identify homologous cell types irrespective of their tissues and
species of origin (55–57).
Conclusion and Perspectives
While it might be the case in the future for single cell RNA-
seq, currently no single method is sufficient to allow the best
possible classification of DC. Hence, ideally, all available methods
(cell surface phenotyping, gene expression profiling, functional
analyses, and ontogeny) should be combined together to define
DC subset identity. However, such a combination of approaches
cannot be used to define cell subsets in many instances due to
technical, financial, or ethical limitations. Taking these limitations
into consideration, the data reviewed here show that comparative
transcriptomics at the population level is currently themost robust
TABLE 2 | Genes which selective expression pattern in immune cell types was uncovered through comparative genomics and which functions in these
cells were deciphered later.
Transcriptomic signaturea Gene symbol (alias) Function
pDC PACSIN1 Necessary for pDC production of type I interferons upon TLR7/9 stimulation (115)
RUNX2 Necessary for terminal differentiation of pDC in, and their egress from, bone marrow (114)
TCF4 (E2-2) Master transcription factor instructing pDC development and functions (113)
BCL11A Necessary for pDC development (116, 117)
cDC ZBTB46 (BTBD4) Transcription factor that appears to be a specific marker of the cDC and endothelial lineages and which
limits spontaneous cDC maturation (118, 119, 128)
BATF3 (9130211I03Rik) Transcription factor which can be critical for development of XCR1+ cDC depending on the context (121)
cDC above pDC BCL6 Promotes the development of XCR1+ cDC (99, 120)
XCR1+ cDC above
XCR1  cDC and pDC
TLR3 TLR3 triggering induces a very strong activation of mouse and human XCR1+ cDC including a uniquely
high production of IFN-β and type III IFN (41, 100, 129, 130)
RAB11A Functionally promotes cross-presentation by storing MHC class I in a unique endosomal recycling
compartment (122)
Mouse XCR1+ cDC XCR1 Likely promotes efficient interactions between XCR1+ cDC and NK cells or CD8+ T cells (18, 36)
Pan-T cells THEMIS (E430004N04Rik) Sets the signal threshold for positive and negative selection of developing T cells in the thymus (124–127)
BCL11B Regulates critical aspects of the development, functions, and homeostasis of T cells (123)
aTranscriptomic signatures conserved between mouse and human unless specified otherwise, first reported in Robbins et al. (39), and encompassing the genes listed in this table.
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and feasible way to define the identity of cell types. Indeed,
because the ontogeny and functions of cell types are instructed by
specific gene expressionmodules, cell type identity can be defined
in a universal and unbiased way by its molecular fingerprinting,
including through gene expression profiling (81). However, due
to its dependency on pre-selection of cell populations based on
their expression patterns of a few cell surface molecules, gene
expression profiling at the cell population level is imperfect and
may require iterative steps of refined cell type isolation and gene
expression profiling as illustrated in Figure 3. Hence, it is all the
more important that each step of the procedure is performed and
rigorously quality controlled according to the best standards in the
field.
Cell purity is fundamental. It is important to design a sampling
method specific for each study, through identification of the most
robust criteria available in the current state of the art for purifica-
tion of the target cell type based on phenotypic, morphologic, or
anatomical characteristics. Cell enrichment is necessary for rare
cell types among bulk populations. It relies on the depletion of
other populations (MACS or EasySep™ for instance). The marker
combination for negative selection must not unwillingly remove a
population of interest. For instance, some antibody cocktails for
human DC enrichment use anti-CD16 monoclonal antibodies,
so as to deplete NK cells, but this should be proscribed for the
study of non-classical, CD16+ monocytes. Positive selection by
magnetic or flow cytometry sorting is most often required after
cell enrichment. Antibody labeling must be clear-cut, with sepa-
rate peaks and/or selection of the events with the highest labeling
and the lowest potential contamination by other populations.
This selection implies the use of marker combinations specific
for the population of interest, since specific markers are rarely
available. XCR1 is a rare instance of a conservedmarker so far only
expressed on a discrete DC population. To the best of our knowl-
edge, reliable commercial reagent are available for XCR1 staining
only for mouse and rat, but XCR1 staining can also be achieved
with fluorescently labeled recombinant XCL1 (40, 41, 52), a strat-
egy that is amenable to many species in which XCL1 sequence
is known. CLEC4C alias BDCA2 and LILRA4 alias ILT7 are
specific markers for human pDC, but their engagement induces
inhibitory signals which for instance reduce pDC production of
type I interferons after stimulation (43, 77–79, 131). Although
selectively expressed at high levels on human pDC in the blood
or lymphoid organs under steady-state conditions, NRP1 alias
BDCA4 can be induced on activated cDC and is also expressed
on other cell types including neurons, endothelial cells, and tumor
cells (132, 133). CD123 is a good marker to help identifying pDC
in non-human primates, but it also labels mastocytes which are
present in the blood or in lymphoid organs (134). Cell purity must
be controlled in each experiment, by flow cytometry re-analysis
just after sorting, and as one of the first step of transcriptomic anal-
ysis by examining the expression of negative and positive control
genes (expression of genes that should be expressed only on other
populations including potential contaminants, and expression of
genes characteristic for the population of interest including but
not restricted to genes coding for the molecules used for positive
selection) (Figure 3).
The quality and quantity of mRNA must be adequate, even
when cell numbers are low. RNA extraction kits adapted to low
cell number samplesmay be required.mRNAqualitymust be con-
trolled by electrophoresis. A linear amplification protocol must be
used, that has been validated for yielding results from low input
RNA showing a strong correlation with the results obtained with
higher RNA input and a classical amplification procedure.
For bioinformatics analyses, the dataset must include sister cell
types as well as the cell types the most likely to contaminate the
cell type of interest, or at least be compatible for integrative anal-
ysis with a reference dataset including these control populations.
Several independent methods for data analysis should be used, to
ensure robustness of interpretation. Beyond relative classification
of the cell types of the dataset by classical approaches comput-
ing the overall distance between their gene expression programs
as performed by hierarchical clustering or principal component
analysis, the identity of cell types can also be reliably inferred from
the analysis of their relative expression of robust cell type-specific
gene signatures established from re-analysis of public gene chip
databases and/or from published articles.
Novel advances are being brought through molecular profiling
of subsets of mononuclear cells. In addition to steady-state con-
ditions, populations can be analyzed after stimulation to identify
the specific activation pathways elicited in pure cell populations or
upon interaction between different cell types (41, 97, 135–137). In
addition to unbiased analysis of the cellular composition of differ-
ent organs (91, 93), transcriptomic profiling at the single cell level
will allow studying heterogeneity in gene expression within one
cell type with the hope to link it to functional heterogeneity (138)
and eventually with the former history/epigenetic imprinting of
each cell. Comparative transcriptomic studies allowed us and
others to identify in humans, non-human primates, pig, sheep,
and chicken cDC subsets homologous to those well described
in mice (5, 18, 39, 50, 52, 62, 76, 83–85). These studies suggest
that similar cDC subsets already existed in the last common
ancestor of birds and mammals. Conserved gene modules appear
during evolution to elicit new functions (81, 82). For instance,
regarding T helper lineage diversification during evolution, con-
trary to bony fishes, the elephant shark, a cartilaginous fish, has
been reported to lack genes encoding for critical transcription
factors or cytokines instructing the development or involved in
the functions of Th2, Th17, and Treg cells, such as RORC and
FOXP3, IL-4, IL-21, IL-23, and IL-2 (139). This suggests that
the genes required for the development of the different T helper
lineages might have appeared progressively as modules during
evolution starting in bony fishes and with late development of the
Treg and Th17 lineages (81). Comparative genomics of mononu-
clear phagocyte subsets and single cell gene expression profil-
ing will critically help identifying novel gene modules and their
associated immune functions. In pDC, evolutionarily conserved
co-expression of TCF4, RUNX2, TLR7, TLR9,UNC93B1,MYD88,
IRAK4, IRF7, and PACSIN1 might represent part of a gene mod-
ule instructing the functional specialization of this cell type in
high level production of type I interferon in response to sensing
of oligonucleotide sequences of viral or autologous origin. In
XCR1+ cDC, evolutionarily conserved co-expression ofCLEC9A,
SYK, RAB11A, RAB7B, SEPT3, SNX22, TLR3,CADM1, andXCR1
might represent part of a gene module instructing the func-
tional specialization of this cell type in CD8+ T-cell activation
and specifically in cross-presentation of cell-associated antigens.
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In any case, the discovery of the sets of genes that are tightly
co-expressed in DC subsets across various tissues and species,
not only at the population level but also at the single cell level,
should allow identifying the gene modules instructing DC subset
functions. Characterization of themembers of these genemodules
which role in DC is unknown yet should strongly contribute to
increase our knowledge on DC subset functional specialization
and their molecular regulation. Of note, not all of these gene
modules might harbor the same differential pattern of expression
between DC subsets in different animal species. Some functions
have gained or lost expression in specific cell subsets in some
species which should correlate with similar changes in the expres-
sion patterns of the corresponding gene modules. For instance,
IL-12 is produced both by pDC and cDC in mice, but only
by cDC in humans, while antigen cross-presentation appears to
be more strongly associated with XCR1+ cDC in mice than in
humans (18, 19, 22). Isolation and comparison of mononuclear
phagocyte subsets from homologous organs in different species
may help understand how the anatomical compartmentalization
of these cells is established and affects their functions, including
local interaction with specific cell types and chemokines. Dating
when during evolution pDC as well as classical and non-classical
monocyte subsets appeared, and in which anatomical compart-
ments they reside in the species the most distant to humans and
mice, may give novel insights into the core functions of these
populations.
In vivo manipulation of DC can promote and orient immune
responses based on the intrinsic functional properties of the DC
subset targeted and can be advantageously used for prophylactic
vaccination or immunotherapy against cancer or infections. This
strategy can benefit from the knowledge gained from the expres-
sion profiling of DC subsets and their alignment across species.
Notably, based on their homology with mouse XCR1+ cDC,
humanXCR1+ cDC can be considered as a promising target when
cross-presentation is desirable, in particular for fighting cancer
or infections by intracellular pathogens (23, 24, 29, 72, 73, 140–
143).Moreover, because it is specifically expressed in XCR1+ cDC
in a conserved manner in evolution, and it has been successfully
used for in vivo delivery of antigens specifically to XCR1+ cDC
to vaccinate mice (23, 24), XCR1 can be considered for a universal
DC targeting strategy in potentially all vertebrate species. Interest-
ingly, the targeting of XCR1 can be achieved with targeting units
composed of recombinant XCL1 fused to protective antigens in
the form of vaccibodies (24), a strategy that is amenable to many
species in which the XCL1 sequence is known. Although more
broadly expressed in the DC lineage at least in mice, CLEC9A
is also an interesting target since it directly promotes cross-
presentation of the material it binds, probably by delivering it into
appropriate endosomes (144, 145), and because it is selectively
expressed to high levels on XCR1+ cDC in humans, sheep, and
mice (25, 32, 76, 146) although itmay not be the case in some other
species such as pig. Arguments in favor or against the targeting
of XCR1+ cDC in the clinic are summarized in Table 3. The
identification of XCR1+ cDC in companion and sport animals,
and in animals of the agro-economy, such as ruminants, pigs,
poultry, and fishes, will allow designing better vaccines to protect
TABLE 3 | The PROs and CONs for in vivo targeting of XCR1+ cDCa.
PROs CONs
Cross-presentation
efficiency
Higher for blood and skin XCR1+ cDC, especially for cell-associated antigens Disputed for XCR1+ cDC from secondary
lymphoid organs (19, 22) depending on
intracellular compartment of antigen delivery (21)
Anatomical
localization
Present in lymphoid and non-lymphoid tissues, enabling subcutaneous, intradermal, or
oral vaccination
Low efficiency of human XCR1+ cDC for
induction of mucosa-homing CD8+ T cells (151)?
Frequency Few cells can mediate important functions in vivo. Quality matters more than quantity Very few numbers of XCR1+ cDC in most tissues
Specificity of
targeting
Very specific expression of XCR1 as opposed to the broader expression of CD141,
DEC205, and CLEC9A. Precise targeting and better pharmacodynamics
Too specific, limiting biological effect to just one
DC subset, may not induce strong enough or
broad enough immune responses
Responsiveness to
adjuvants
Very good responsiveness to PolyI:C. PolyI:C is a very potent adjuvant for the induction
of strong, polyfunctional CD8+ T-cell responses which might result in part from TLR3
triggering in XCR1+ cDC
PolyI:C may primarily work by activating other
targets, i.e., non-immune cells expressing TLR3
or cells activated through MDA5
Proof of concept
achieved in mice
XCR1+ cDC are critical for anti-tumoral responses in mice (72, 121, 152, 153). XCR1
targeting works in mice (23, 24). XCR1 bio-equivalency in human, macaques, mouse,
pig, and sheep, same gene expression pattern and biological function. Hence, higher
probability of translation to human of mechanistic studies in animals
Many previous failures of mouse to human
translation
In vitro model Ability to generate in vitro and manipulate bona fide human XCR1+ cDC from CD34+
cord blood progenitors (41, 65, 66, 69, 111, 112)
Cytokine
production
XCR1+ cDC can produce IL-12 but maybe optimal conditions to induce this function
remain to be identified (50, 65, 66, 143). Mouse and human XCR1+ cDC are high
producers of beta and type III interferons upon PolyI:C stimulation (41, 100, 129, 130)
Human XCR1+ cDC are very poor producers of
IL-12 (70, 108)
Clinical data Gene expression profiling of human tumors suggest that infiltration by XCR1+ cDC but
not other myeloid cells is of good prognosis both in mice and humans (72)
Formal measurements of XCR1+ cDC infiltration
in human tumors and of its beneficial role for
disease control remain to be established
aMore details and bibliographical references can be found in the main text of this review.
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TABLE 4 | Practical guidelines for consistent definition of DC subsets across mouse and human tissues with potential applicability to other mammals.
Characterization XCR1  cDC2 XCR1+ cDC1 pDC
High or positive Negative
or low
High or positive Negative
or low
High or positive Negative
or low
Conserved
phenotype
CD11chigh CD3  CD11clow-to-high CD3  MHC-IIint CD3 
MHC-IIhigh CD19  MHC-IIhigh CD19  FLT3+ CD19 
FLT3+ CD14 /low FLT3+ CD14 /low CD14 /low
SIRPα+ CD206 /low XCR1+ CD206 /low CD206 /low
CD123  CADM1+ CD123  CD19 
Critical
species-specific
phenotypic markers
Mouse: Siglec-H or Ccr9
Human: CD123 and CLEC4C
(BDCA2) or ILT7 (LILRA4)
Hallmark genes (18,
37, 39)
FLT3 XCR1 FLT3 TLR4 FLT3 XCR1
TLR8 RAB7B XCR1 TLR7 TLR7 CADM1
ZBTB46 GCET2 CADM1 IRF4 TLR9 TLR3
IRF4a TLR4 TLR3 TCF4 PACSIN1 TLR8
IRF8 RAB7B RUNX2 IRF8 RAB7B
TCF4 GCET2 SPIB TCF4 GCET2
RUNX2 ZBTB46 RUNX2 ZBTB46
SPIB IRF8 SPIB BATF3
BATF3 BCL11A CADM1
Hallmark cytokine
production
IL-23
production? (62)
Type III interferon production upon TLR3
triggering (41, 100, 129, 130)
Production of type I and III
interferons in response to
TLR7/9 triggering
Hallmark antigen-
presentation
functions
High efficiency
for CD4+ T-cell
activation
High efficiency for CD8+ T-cell activation,
in particular through cross-presentation
of cell-associated antigens
aMaster transcription factors critical for cell subset development are indicated in bold font.
them against infections in order to ameliorate animal welfare and
to prevent pandemics causing severe economic losses. It will also
contribute to a global public health strategy because some of these
animal species as well as wild animals are targets or reservoirs
for major zoonotic pathogens. The identification of XCR1+ cDC
in rhesus macaques and in pigs opens the way to preclinical
vaccination studies in these species which are close to humans.
Vaccibodies based on XCL1 dimers coupled to influenza or SIV
proteins are planned to be used for vaccination of pigs or rhesus
macaques, respectively, and induction of immune responses and
protection against infection. pDC targeting could also be consid-
ered as an interesting alternative for vaccination against viruses or
tumors (20, 147, 148), or for the induction of cross-tolerance to
treat autoimmune diseases or food allergies (149, 150).
A synthetic list of phenotypic, transcriptomic, and functional
hallmarks which have already allowed conserved identification
of different DC and monocyte subsets in humans and mice is
presented in Table 4. The present Special Issue and future work-
shop on DC nomenclature will help reach a consensus panel
for practical definition of the populations, in order to integrate
faster the huge, but scattered knowledge accumulated by different
laboratories in different cell types, species, and organs.
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